Table 3.

Details on the cardiovascular events and cardiologic treatments of the CVE group.

Patient	First LVEF (%)	Last LVEF (%)	Lowest LVEF (%)	Chemotherapy administered before lower LVEF or CVE onset	CVE manifestation	Details on cardiotoxicity	Onset of CVE	Cardiac treatment
Patient 1	73	50	48	MTX+VCR, VP16, HD-Cyclophosphamide, Carboplatin	Asymptomatic LV dysfunction	BNP elevation, abnormalities of ventricular repolarization at EKG hypokinesia of the interventricular septum,	Acute	Diuretics, β-blockers, inotropes
Patient 2	70	62	48	MTX+VCR, VP16	Symptomatic LV disfunction	Rest dyspnea, tachycardia, BNP elevation, prolonged QTc interval at EKG, hypokinesia of the interventricular septum, mild pericardial effusion, mild mitral and tricuspid valve regurgitation	Acute	Diuretics, β-blockers, ACE inhibitors
Patient 3	73	62	45	MTX+VCR, VP16, HD-Cyclophosphamide, Carboplatin, Thiotepa	Asymptomatic LV dysfunction	BNP elevation, reduced QRS voltages in all EKG leads, increased left ventricular volume, mild mitral and tricuspid valve regurgitation	Chronic	Diuretics, β-blockers, inotropes
Patient 4	67	68	66	MTX+VCR, VP16	Arterial hypertension	None	Acute	ACE inhibitors
Patient 5	Not Available	62	62	MTX+VCR, VP16, HD-Cyclophosphamide, Carboplatin, Thiotepa	Ectopic atrial tachycardia	Prolonged QTc interval at EKG	Chronic	β-blockers
Patient 6	70	75	58	MTX+VCR, VP16, Cyclophosphamide, Carboplatin, Thiotepa, Temozolomide	Hypokinesia of the interventricular septum with dyspnea and BNP elevation	Arterial hypertension, acute prerenal renal failure, mild pericardial effusion, mild aortic, mitral and tricuspid valves regurgitation	Chronic	Diuretics, ACE inhibitors

List of abbreviations: ACE, angiotensin converting enzyme; BNP, brain natriuretic peptide; CVE, cardiovascular events; EKG, electrocardiogram; HD, high dose; LV, left ventricular; LVEF, left ventricular ejection fraction; MTX, methotrexate; VCR, vincristine; VP16, etoposide.